Pfizer Inc has said that its antiviral COVID-19 has about 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the Omicron variant of the coronavirus.

Pfizer covid-19 pill nearly 90% effective against Omicron variant of Coronavirus

Latest variant of coronavirus Omicron variant has been found in 57 countries across the world while scientists are still studying the transmissibility of the variant, concerns of Omicron are only increasing. In the latest, three-shot course can neutralize Omicron variant.

Pfizer: Booster promising against Omicron | Coronavirus News

A major real-world study has suggested that Pfizer Covid vaccine has weaker efficacy against the Omicron variant. The study revealed that the Pfizer vaccine had efficacy of just 70 per cent against hospitalisation.

The study released on Tuesday by South Africa's largest private health insurance administrator, Discovery Health, was based on more than 211,000 positive COVID-19 test results. Around 78,000 of those results from Nov. 15 to Dec. 7 were attributed to Omicron.

The 78,000 results are not confirmed Omicron cases, meaning the study cannot offer conclusive findings about the variant labelled "of concern" by the World Health Organization and reported in more than 60 countries.

South African scientists have so far confirmed around 550 positive tests as being Omicron, with the variant accounting for 78% of sequences from November, more than the previously dominant Delta variant.

South Africa alerted the world to Omicron late last month, triggering alarm that it could cause another surge in global infections, and leading to the imposition of travel restrictions on southern Africa. South Africa's daily infections have since risen to around 20,000 in recent days.

The findings from a real-world analysis are some of the earliest on protection against Omicron outside of lab studies, which have shown reduced neutralising activity against the variant. read more

Based on analysis by Discovery's clinical research and actuarial teams, and in collaboration with the South African Medical Research Council, the study calculated that two doses of Pfizer-BioNTech offered 70% protection against hospitalisation compared with the unvaccinated during the recent surge in cases and 33% protection against infection.

It said this represents a drop from 80% protection against infection and compares with 93% efficacy against hospital admission during South Africa's outbreak of the Delta variant, which is the globally dominant variant and considered to be the most infectious to emerge during the pandemic.

Discovery cautioned that the study's findings should be considered preliminary.

(With inputs from agencies)

A major real-world study has suggested that Pfizer Covid vaccine has weaker efficacy against the Omicron variant. The study revealed that the Pfizer vaccine had efficacy of just 70 per cent against hospitalisation.

A major real-world study has suggested that Pfizer Covid vaccine has weaker efficacy against the Omicron variant. The study revealed that the Pfizer vaccine had efficacy of just 70 per cent against hospitalisation. The study released on Tuesday by South Africa's largest private health insurance administrator, Discovery Health, was based on more than 211,000 positive COVID-19 test results. Around 78,000 of those results from Nov. 15 to Dec. 7 were attributed to Omicron. The 78,000 results are not confirmed Omicron cases, meaning the study cannot offer conclusive findings about the variant labelled "of concern" by the World Health Organization and reported in more than 60 countries. South African scientists have so far confirmed around 550 positive tests as being Omicron, with the variant accounting for 78% of sequences from November, more than the previously dominant Delta variant. South Africa alerted the world to Omicron late last month, triggering alarm that it could cause another surge in global infections, and leading to the imposition of travel restrictions on southern Africa. South Africa's daily infections have since risen to around 20,000 in recent days. The findings from a real-world analysis are some of the earliest on protection against Omicron outside of lab studies, which have shown reduced neutralising activity against the variant. read more Based on analysis by Discovery's clinical research and actuarial teams, and in collaboration with the South African Medical Research Council, the study calculated that two doses of Pfizer-BioNTech offered 70% protection against hospitalisation compared with the unvaccinated during the recent surge in cases and 33% protection against infection. It said this represents a drop from 80% protection against infection and compares with 93% efficacy against hospital admission during South Africa's outbreak of the Delta variant, which is the globally dominant variant and considered to be the most infectious to emerge during the pandemic. Discovery cautioned that the study's findings should be considered preliminary. (With inputs from agencies)

Pfizer vaccine less effective against Omicron variant, claims study

A 26-year-old man's death in New Zealand has been linked to a side effect from Pfizer's Covid vaccine after he died within two weeks of receiving it. After taking his first dose, the person suffered from myocarditis, which is a rare inflammation of the heart muscle.

The man had not taken any medical advice or treatment for his symptoms.&nbsp;

New Zealand’s Covid vaccine independent safety monitoring board in a statement said, "With the current available information, the board has considered that the myocarditis was probably due to vaccination in this individual."

In response, a Pfizer spokesperson said that the company was aware of the incident in New Zealand, and it had monitored all reports of possible adverse events. He further mentioned that it will continue to believe the benefit-risk profile for its vaccine was positive.

<a href="https://www.wionews.com/world/christmas-travel-can-lead-to-doubling-of-omicron-cases-fauci-438291">Also read |&nbsp;Christmas travel can lead to doubling of Omicron cases: Fauci</a>

Earlier, in August, a woman in New Zealand died after she was administered the Pfizer Covid vaccine.&nbsp;

The health ministry said, "This is the first case in New Zealand where a death in the days following vaccination has been linked to the Pfizer Covid vaccine."

The health ministry further added that the cause of death has not yet been determined while asserting that, "the benefits of vaccination with the Pfizer COVID-19 vaccine continue to greatly outweigh the risk of both Covid infection and vaccine side effects, including myocarditis."

Earlier, the World Health Organization had acknowledged that "a very rare signal of myocarditis" has been reported from some Covid vaccines. The organization further added that most myocarditis cases occur in young men aged between 16 to 24.

(With inputs from agencies)

A 26-year-old man's death in New Zealand has been linked to a side effect from Pfizer's Covid vaccine after he died within two weeks of receiving it. After taking his first dose, the person suffered from myocarditis, which is a rare inflammation of the heart muscle.

A 26-year-old man's death in New Zealand has been linked to a side effect from Pfizer's Covid vaccine after he died within two weeks of receiving it. After taking his first dose, the person suffered from myocarditis, which is a rare inflammation of the heart muscle. The man had not taken any medical advice or treatment for his symptoms. New Zealand’s Covid vaccine independent safety monitoring board in a statement said, "With the current available information, the board has considered that the myocarditis was probably due to vaccination in this individual." In response, a Pfizer spokesperson said that the company was aware of the incident in New Zealand, and it had monitored all reports of possible adverse events. He further mentioned that it will continue to believe the benefit-risk profile for its vaccine was positive. Also read | Christmas travel can lead to doubling of Omicron cases: Fauci Earlier, in August, a woman in New Zealand died after she was administered the Pfizer Covid vaccine. The health ministry said, "This is the first case in New Zealand where a death in the days following vaccination has been linked to the Pfizer Covid vaccine." The health ministry further added that the cause of death has not yet been determined while asserting that, "the benefits of vaccination with the Pfizer COVID-19 vaccine continue to greatly outweigh the risk of both Covid infection and vaccine side effects, including myocarditis." Earlier, the World Health Organization had acknowledged that "a very rare signal of myocarditis" has been reported from some Covid vaccines. The organization further added that most myocarditis cases occur in young men aged between 16 to 24. (With inputs from agencies)

Young man's death in New Zealand linked to Pfizer Covid vaccine after he suffered from myocarditis

Amid growing concerns over the new Coronavirus (COVID-19) variant, Pfizer Inc said on Friday the pandemic could extend through next year. The vaccine making company also announced plans to come up with a three-dose vaccine regimen for children aged 2 to 16.&nbsp;

If we talk about the new variant, initial data suggests that Omicron is more transmissible than the Delta and can be resistant to available vaccines.&nbsp;

The United Kingdom is among the hardest-hit countries by Omicron variant as London mayor Sadiq Khan declared a "major incident" in the British capital (on saturday) owing to the spread of the new variant.&nbsp;

ALSO READ | <a href="https://www.wionews.com/world/can-omicron-and-delta-unite-to-create-an-even-worse-covid-19-variant-expert-has-the-answer-437905">Can Omicron and Delta unite to create an even worse COVID-19 variant? Expert has the answer</a>

Also, Dutch Prime Minister Mark Rutte announced that the Netherlands will go into "lockdown" over the Christmas period to try to stop a surge of the Omicron variant.&nbsp;

Meanwhile, Pfizer executives said the company believed that by 2024, the disease should be endemic around the globe, meaning it would no longer be a pandemic. The company projected that "COVID will transition to an endemic state potentially by 2024."

ALSO READ |&nbsp;<a href="https://www.wionews.com/world/covid-19-experts-name-one-common-symptom-of-omicron-variant-437842">COVID-19: Experts name one common symptom of Omicron variant</a>

Announcing plans to develop a three-dose regimen for ages 2 to 16, Chief Scientific Officer Mikael Dolsten told a conference call that results of three doses among people older than 16 showed that the approach offered greater protection.

"Therefore, we have decided to modify each of the pediatric studies to incorporate a third dose to the series and seek licensure for a three-dose series rather than a two-dose series as originally anticipated," the company said.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/covid-19-news-update-53-million-died-due-to-different-strains-of-coronavirus-438046/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

&nbsp;

(With inputs from agencies)

Amid growing concerns over the new Coronavirus (COVID-19) variant, Pfizer Inc said on Friday the pandemic could extend through next year. The vaccine making company also announced plans to come up with a three-dose vaccine regimen for children aged 2 to 16.

Amid growing concerns over the new Coronavirus (COVID-19) variant, Pfizer Inc said on Friday the pandemic could extend through next year. The vaccine making company also announced plans to come up with a three-dose vaccine regimen for children aged 2 to 16. If we talk about the new variant, initial data suggests that Omicron is more transmissible than the Delta and can be resistant to available vaccines. The United Kingdom is among the hardest-hit countries by Omicron variant as London mayor Sadiq Khan declared a "major incident" in the British capital (on saturday) owing to the spread of the new variant. ALSO READ | Can Omicron and Delta unite to create an even worse COVID-19 variant? Expert has the answer Also, Dutch Prime Minister Mark Rutte announced that the Netherlands will go into "lockdown" over the Christmas period to try to stop a surge of the Omicron variant. Meanwhile, Pfizer executives said the company believed that by 2024, the disease should be endemic around the globe, meaning it would no longer be a pandemic. The company projected that "COVID will transition to an endemic state potentially by 2024." ALSO READ | COVID-19: Experts name one common symptom of Omicron variant Announcing plans to develop a three-dose regimen for ages 2 to 16, Chief Scientific Officer Mikael Dolsten told a conference call that results of three doses among people older than 16 showed that the approach offered greater protection. "Therefore, we have decided to modify each of the pediatric studies to incorporate a third dose to the series and seek licensure for a three-dose series rather than a two-dose series as originally anticipated," the company said. × (With inputs from agencies)

Pfizer says COVID-19 pandemic could extend to 2024

The Brazilian president Jair Bolsonaro has threatened to disclose identities of health officials who played a part in approving Covid vaccines for children. <o:p></o:p>

Bolsonaro's threat has come after Brazil’s health regulator, Anvisa, revealed that the organisations’s five directors had recently received death threats over the fact that they had played a part in approval of vaccinations for children aged between five and eleven.<o:p></o:p>

While Anvisa approved the Covid vaccine for kids, it is not yet decided if the kids will start getting vaccinated just yet or not.&nbsp;The matter has been passed to the health ministry for further consideration.

<o:p><a href="https://www.wionews.com/videos/omicron-variant-spreads-across-the-world-with-uk-covid-19-cases-surging-to-a-record-high-437816">WATCH |</a></o:p>

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/omicron-variant-spreads-across-the-world-with-uk-covid-19-cases-surging-to-a-record-high-437816/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

"Collective vaccination reduces transmission of SARS-CoV-2 for this age group, and as a result, reduces transmission from children and adolescents to adults and the elderly," said Meiruze Freitas, director of Brazilian health regulator Anvisa, announcing the decision.<o:p></o:p>

Since Anvisa had granted approval for Pfizer shot for children on Thursday, some locals have been protesting vocally against it and have also reportedly sent death threats to officials.<o:p></o:p>

Anvisa has reported the threats to the police and prosecutors.<o:p></o:p>

However, Bolsonaro decided that the logical move was to reveal the names of all the officials who have helped in getting the approval for Pfizer vaccine for children. Bolsonaro believes that the names should be revealed so that the public "could come to its own judgements".<o:p></o:p>

Bolsonaro has suffered immense backlash for his poor handling of the coronavirus pandemic in Brazil. The President earlier downplayed by pandemic by claiming that the COVID-19 was not a 'big deal'. He has also, several times, broken Covid restrictions imposed by health experts and has in some ways promoted vaccine hesitancy in Brazil.<o:p></o:p>

The Brazilian president Jair Bolsonaro has threatened to disclose identities of health officials who played a part in approving Covid vaccines for children. Bolsonaro's threat has come after Brazil’s health regulator, Anvisa, revealed that the organisations’s five directors had recently received death threats over the fact that they had played a part in approval of vaccinations for children aged between five and eleven.

The Brazilian president Jair Bolsonaro has threatened to disclose identities of health officials who played a part in approving Covid vaccines for children. Bolsonaro's threat has come after Brazil’s health regulator, Anvisa, revealed that the organisations’s five directors had recently received death threats over the fact that they had played a part in approval of vaccinations for children aged between five and eleven. While Anvisa approved the Covid vaccine for kids, it is not yet decided if the kids will start getting vaccinated just yet or not. The matter has been passed to the health ministry for further consideration. WATCH | "Collective vaccination reduces transmission of SARS-CoV-2 for this age group, and as a result, reduces transmission from children and adolescents to adults and the elderly," said Meiruze Freitas, director of Brazilian health regulator Anvisa, announcing the decision. Since Anvisa had granted approval for Pfizer shot for children on Thursday, some locals have been protesting vocally against it and have also reportedly sent death threats to officials. Anvisa has reported the threats to the police and prosecutors. However, Bolsonaro decided that the logical move was to reveal the names of all the officials who have helped in getting the approval for Pfizer vaccine for children. Bolsonaro believes that the names should be revealed so that the public "could come to its own judgements". Bolsonaro has suffered immense backlash for his poor handling of the coronavirus pandemic in Brazil. The President earlier downplayed by pandemic by claiming that the COVID-19 was not a 'big deal'. He has also, several times, broken Covid restrictions imposed by health experts and has in some ways promoted vaccine hesitancy in Brazil.

Bolsonaro threatens disclosing names of officials who approved Covid jabs for children

On Thursday, a panel of US government-appointed medical experts unanimously recommended Pfizer's and Moderna's mRNA Covid vaccines over Johnson &amp; Johnson's due to its weaker protection and greater risks.&nbsp;

There was a 15-0 vote in favour of the new guidance, which applies to everyone over the age of 18.

Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), signed off on the measure Thursday evening. "Today's updated recommendation emphasizes CDC's commitment to provide real-time scientific information to the public," she said in a statement, encouraging American citizens to get vaccinated and get coronavirus booster shots.

Also read |&nbsp;<a href="https://www.wionews.com/world/eu-drug-regulator-gives-go-ahead-for-pfizer-covid-pills-emergency-use-437518" hreflang="en">EU drug regulator gives go-ahead for Pfizer Covid pill's emergency use</a>

The recommendation steers the public away from J&amp;J's drug, which initially won praise in part because it could be stored at room temperature and performed well against earlier strains of the Coronavirus after just one shot.

However, it was later linked to clotting, especially among women of childbearing age, which led authorities to temporarily suspend its use then resume it in April. Since then, it has remained a distant third choice of vaccination among Americans.

It was discovered this week that this clotting effect is more prevalent than initially thought, and not necessarily restricted to females.

Additionally, preliminary laboratory testing indicates that the jab provides little protection against the new Omicron variant -- at least against infection.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/omicron-uk-reports-over-88000-covid-cases-highest-daily-since-pandemic-began-437395" hreflang="en">Omicron: UK reports over 88,000 Covid cases, highest daily since pandemic began</a>

CDC called the vote after new safety data raised concerns.&nbsp;

According to new data released by the CDC, nine people have died so far because of low platelet counts or Thrombosis with Thrombocytopenia Syndrome (TTS), with around 16 million doses of vaccine administered.

As of August 31, there were 54 cases, 36 of which required intensive care. The survivors had long-term effects such as paralysis in some cases.

Women aged 30-49 were at the greatest risk, where TTS occurred at around a rate of one in 100,000.

The risk, however, isn't limited to women, with two of the nine deaths occurring among men. Additionally, the CDC said the death toll may be underestimated.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/covid-vaccines-likely-to-be-less-effective-against-omicron-variant-who-437383" hreflang="en">Covid vaccines likely to be less effective against Omicron variant: WHO</a>

TTS has caused fatalities in about one out of seven cases.&nbsp;

CDC scientist Sara Oliver told a committee of independent experts, they had several choices, including recommending not to use the vaccine altogether.&nbsp;

The panel of experts agreed, however, that the J&amp;J vaccine should remain available for people who, for whatever reasons, may refuse mRNA vaccines, despite their higher efficacy and lower risks.&nbsp;

In its discussion of risks and benefits, the CDC also said that the Pfizer and Moderna vaccines carry risks, primarily for younger men who may in very rare cases develop myocarditis or pericarditis -- inflammation of or around the heart.&nbsp;

Watch |&nbsp;Gravitas: Lab leak "most likely" source of Covid-19, British MPs told

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-lab-leak-most-likely-source-of-covid-19-british-mps-told-437529/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

No fatalities have been reported from these cases, and the two vaccines offer a much greater level of protection than the J&amp;J shot.

"The Johnson and Johnson Covid-19 vaccine is a life saving tool for individuals in high risk populations," Penny Heaton, global therapeutic area head of vaccines at J&amp;J argued.

The panel agrees with the company that recommending against the J&amp;J shot completely would send an undesirable message to other areas of the world where the jab may be the only option.&nbsp;

(With inputs from agencies)

On Thursday, a panel of US government-appointed medical experts unanimously recommended Pfizer's and Moderna's mRNA Covid vaccines over Johnson & Johnson's due to its weaker protection and greater risks.

On Thursday, a panel of US government-appointed medical experts unanimously recommended Pfizer's and Moderna's mRNA Covid vaccines over Johnson & Johnson's due to its weaker protection and greater risks. There was a 15-0 vote in favour of the new guidance, which applies to everyone over the age of 18. Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), signed off on the measure Thursday evening. "Today's updated recommendation emphasizes CDC's commitment to provide real-time scientific information to the public," she said in a statement, encouraging American citizens to get vaccinated and get coronavirus booster shots. Also read | EU drug regulator gives go-ahead for Pfizer Covid pill's emergency use The recommendation steers the public away from J&J's drug, which initially won praise in part because it could be stored at room temperature and performed well against earlier strains of the Coronavirus after just one shot. However, it was later linked to clotting, especially among women of childbearing age, which led authorities to temporarily suspend its use then resume it in April. Since then, it has remained a distant third choice of vaccination among Americans. It was discovered this week that this clotting effect is more prevalent than initially thought, and not necessarily restricted to females. Additionally, preliminary laboratory testing indicates that the jab provides little protection against the new Omicron variant -- at least against infection. Also read | Omicron: UK reports over 88,000 Covid cases, highest daily since pandemic began CDC called the vote after new safety data raised concerns. According to new data released by the CDC, nine people have died so far because of low platelet counts or Thrombosis with Thrombocytopenia Syndrome (TTS), with around 16 million doses of vaccine administered. As of August 31, there were 54 cases, 36 of which required intensive care. The survivors had long-term effects such as paralysis in some cases. Women aged 30-49 were at the greatest risk, where TTS occurred at around a rate of one in 100,000. The risk, however, isn't limited to women, with two of the nine deaths occurring among men. Additionally, the CDC said the death toll may be underestimated. Also read | Covid vaccines likely to be less effective against Omicron variant: WHO TTS has caused fatalities in about one out of seven cases. CDC scientist Sara Oliver told a committee of independent experts, they had several choices, including recommending not to use the vaccine altogether. The panel of experts agreed, however, that the J&J vaccine should remain available for people who, for whatever reasons, may refuse mRNA vaccines, despite their higher efficacy and lower risks. In its discussion of risks and benefits, the CDC also said that the Pfizer and Moderna vaccines carry risks, primarily for younger men who may in very rare cases develop myocarditis or pericarditis -- inflammation of or around the heart. Watch | Gravitas: Lab leak "most likely" source of Covid-19, British MPs told No fatalities have been reported from these cases, and the two vaccines offer a much greater level of protection than the J&J shot. "The Johnson and Johnson Covid-19 vaccine is a life saving tool for individuals in high risk populations," Penny Heaton, global therapeutic area head of vaccines at J&J argued. The panel agrees with the company that recommending against the J&J shot completely would send an undesirable message to other areas of the world where the jab may be the only option. (With inputs from agencies)

Citing risk of clotting, US expert panel votes for the use of Moderna, Pfizer vaccines, over J&J

The European Medical Agency on Thursday gave go-ahead for emergency use of Pfizer's Covid pill. Formal approval is still pending. The initial go-ahead has been given to curb Omicron infection.

Pills made by Pfizer and Merck are being hailed as groundbreaking because as compared to injections, they can be made accessible readily.

Pfizer said this week that its Paxlovid pill reduced hospitalisations and deaths in vulnerable people by almost 90 percent.

"The medicine, which is not yet authorised in the EU, can be used to treat adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease," the EMA said in a statement.

"EMA issued this advice to support national authorities who may decide on possible early use of the medicine... for example in emergency use settings, in the light of rising rates of infection and deaths due to Covid-19 across the EU."

Pfizer CEO Albert Bourla welcomed the development. He said that the decision "signifies the strength of our data for Paxlovid in the treatment of high-risk adults diagnosed with Covid-19."

"If authorised, Paxlovid has the potential to help save lives and reduce hospitalisations," he said in a statement.

The Pfizer pill is a combination of a new molecule, PF-07321332, and HIV antiviral ritonavir, that are taken as separate tablets.

The Amsterdam-based EMA said it should be taken as soon as possible after a diagnosis and within five days of the start of symptoms, with the treatment lasting five days.

'Combined effect'

Possible side effects were taste changes, diarrhoea and vomiting. Pregnant women should not use the drug.

The EMA said it also launching a "rolling review" of the Pfizer pill that could lead to its full approval in months.&nbsp;

Merck's pill received EMA emergency approval in November. It is already authorised in Britain and is in the process of being approved in the United States.

Denmark on Thursday became the first EU country to approve its use.

However the full results of a clinical trial released by Merck were disappointing as they showed a much lower efficacy than earlier reports based on interim data.

(With inputs from agencies)

The European Medical Agency on Thursday gave go-ahead for emergency use of Pfizer's Covid pill. Formal approval is still pending. The initial go-ahead has been given to curb Omicron infection.

The European Medical Agency on Thursday gave go-ahead for emergency use of Pfizer's Covid pill. Formal approval is still pending. The initial go-ahead has been given to curb Omicron infection. Pills made by Pfizer and Merck are being hailed as groundbreaking because as compared to injections, they can be made accessible readily. Pfizer said this week that its Paxlovid pill reduced hospitalisations and deaths in vulnerable people by almost 90 percent. "The medicine, which is not yet authorised in the EU, can be used to treat adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease," the EMA said in a statement. "EMA issued this advice to support national authorities who may decide on possible early use of the medicine... for example in emergency use settings, in the light of rising rates of infection and deaths due to Covid-19 across the EU." Pfizer CEO Albert Bourla welcomed the development. He said that the decision "signifies the strength of our data for Paxlovid in the treatment of high-risk adults diagnosed with Covid-19." "If authorised, Paxlovid has the potential to help save lives and reduce hospitalisations," he said in a statement. The Pfizer pill is a combination of a new molecule, PF-07321332, and HIV antiviral ritonavir, that are taken as separate tablets. The Amsterdam-based EMA said it should be taken as soon as possible after a diagnosis and within five days of the start of symptoms, with the treatment lasting five days. 'Combined effect' Possible side effects were taste changes, diarrhoea and vomiting. Pregnant women should not use the drug. The EMA said it also launching a "rolling review" of the Pfizer pill that could lead to its full approval in months. Merck's pill received EMA emergency approval in November. It is already authorised in Britain and is in the process of being approved in the United States. Denmark on Thursday became the first EU country to approve its use. However the full results of a clinical trial released by Merck were disappointing as they showed a much lower efficacy than earlier reports based on interim data. (With inputs from agencies)

EU drug regulator gives go-ahead for Pfizer Covid pill's emergency use

After reports claimed Pfizer had shown a "shocking risk level" for its vaccine, a fact-check by AFP revealed it was an inaccurate claim and that there was no causal link established between the problems and the jabs.

After reports claimed Pfizer had shown a "shocking risk level" for its vaccine, a fact-check by AFP revealed it was an inaccurate claim and that there was no causal link established between the problems and the jabs. The report related to recent documents released by the Food and Drug Administration (FDA) which claimed important revelations pertaining to the Pfizer Covid-19 vaccine. The documents which were obtained by a group of doctors, professors, and journalists apparently showed that Pfizer recorded nearly 160,000 adverse reactions to its vaccine during the initial months. As per the documents, over 25,000 nervous system disorders were reported. This was accompanied with 17,000 musculoskeletal and connective tissue disorders and 14,000 gastrointestinal disorders. "The figure of 1,223 fatalities among 158,893 adverse effects reflect "spontaneous" reports from sources that include health officials in several countries, without any verification of the cause, among the millions of vaccinated people worldwide during that period," Pfizer spokeswoman Dervila Keane told AFP. "It does not indicate specific causes of death and the fatalities may include people with "various illnesses" such as cancer or cardiovascular disease," Dervila added. The documents were reportedly obtained after doctors, professors and journalists filed a Freedom of Information Act request with the FDA. The first set of documents claimed that in February 2021, when the shot was being given out on an emergency basis, over 42,000 case were reported. These highlighted nearly 160,000 adverse reactions to the jab which ranged from the mild to severe. Out of these 1,223 are said to be fatal, reports RT. However, FDA spokeswoman Alison Hunt told AFP that it requires health care providers to report any death following vaccination to the system, "even if it's unclear whether the vaccine was the cause." "Reviews by FDA and CDC have determined that the vast majority of the deaths reported are not directly attributable to the vaccines," she said, adding that reports of deaths after Covid-19 vaccination are "rare." All of thee side effects have been mentioned in the Centers for Disease Control and Prevention’s Vaccine Adverse Event Reporting System database. As of Sunday, it had recorded a total of 3,300 deaths following vaccination with the company's vaccine. While some say that these effects and deaths are underreported, critics said that these deaths cannot be linked with vaccination. The AFP fact-check said clinical research indicates no link between the Pfizer-BioNTech vaccine and fatalities. (With inputs from agencies)

Fact-check: Documents claiming Pfizer vaccine led to adverse effects are false

Pharma major Pfizer said on Tuesday that clinical trials showed that its Covid pill drastically reduces probability of hospitalisation and death among at-risk people. The reduction was pegged by the company to be at 90 per cent.

The announcement came as a real-world study from South Africa showed two doses of the Pfizer-BioNTech vaccine was 70 percent effective in stopping severe illness from the new variant, a result called encouraging by researchers, though it represents a drop compared to earlier strains.

Data for the new pill, which hasn't yet been authorised anywhere in the world, came from more than 2,200 volunteers, and backed up preliminary findings announced last month.

The American drugmaker said its treatment, called Paxlovid, also held up against the Omicron variant in lab-testing. 
Pfizer CEO Albert Bourla told CBS News the drug was a "game changer," and he expected the US Food and Drug Administration (FDA) to give its green light as soon as this month.

The trial showed that the pill reduced the need for hospitalisation in high-risk adults with Covid-19 by 89 percent if the treatment was given within three days of symptom onset and by 88 percent if given within five days.

Overall, there were 12 deaths in the placebo group, and none in the drug group.

Side-effects were found at comparable rates between the treatment and placebo groups (23 percent and 24 percent, respectively), and were mostly mild.&nbsp;

Paxlovid also reduced the risk of severe disease, as well as the amount of virus detected, in a separate study of people at normal risk -- but the results were on the edge of statistical significance and need further confirmation.

(With inputs from agencies)

Pharma major Pfizer said on Tuesday that clinical trials showed that its Covid pill drastically reduces probability of hospitalisation and death among at-risk people.

Pharma major Pfizer said on Tuesday that clinical trials showed that its Covid pill drastically reduces probability of hospitalisation and death among at-risk people. The reduction was pegged by the company to be at 90 per cent. The announcement came as a real-world study from South Africa showed two doses of the Pfizer-BioNTech vaccine was 70 percent effective in stopping severe illness from the new variant, a result called encouraging by researchers, though it represents a drop compared to earlier strains. Data for the new pill, which hasn't yet been authorised anywhere in the world, came from more than 2,200 volunteers, and backed up preliminary findings announced last month. The American drugmaker said its treatment, called Paxlovid, also held up against the Omicron variant in lab-testing. Pfizer CEO Albert Bourla told CBS News the drug was a "game changer," and he expected the US Food and Drug Administration (FDA) to give its green light as soon as this month. The trial showed that the pill reduced the need for hospitalisation in high-risk adults with Covid-19 by 89 percent if the treatment was given within three days of symptom onset and by 88 percent if given within five days. Overall, there were 12 deaths in the placebo group, and none in the drug group. Side-effects were found at comparable rates between the treatment and placebo groups (23 percent and 24 percent, respectively), and were mostly mild. Paxlovid also reduced the risk of severe disease, as well as the amount of virus detected, in a separate study of people at normal risk -- but the results were on the edge of statistical significance and need further confirmation. (With inputs from agencies)

Pfizer claims Covid pill drastically reduces severe infection

Pfizer said final analysis of its antiviral COVID-19 pill still showed near 90% efficacy in preventing hospitalisations and deaths in high-risk patients.

Pfizer says its COVID-19 pill shows 90% efficacy, cuts hospitalisation risk

As Omicron cases are rapidly spreading all across the world, a latest study has revealed that a three-shot course of the Pfizer-BioNTech Covid vaccine offers protection against the new variant, Omicron.&nbsp;The study was carried out by the Sheba Medical Center and the Health Ministry’s Central Virology Laboratory.&nbsp;

As a part of the study,&nbsp;a comparison was made between the blood of 20 people who had received two vaccine doses 5-6 months prior to the same number of people who had received a booster just a month before.&nbsp;

The findings are very similar to those of a study presented by Pfizer-BioNTech a week before. The study stated that the vaccine neutralises the Omicron variant of coronavirus.

<a href="https://www.wionews.com/world/study-demonstrates-three-doses-of-pfizer-biontech-vaccine-neutralises-omicron-variant-435221">Also read |&nbsp;Study demonstrates three doses of Pfizer-BioNTech vaccine neutralises Omicron variant</a>

Omicron counts more than 30 mutations on the spike protein. The company has said that although two doses of the vaccine offer a high level of protection, the third jab increases efficacy by 25 per cent.&nbsp;

According to a report by Times of Israel, Prof. Gili Regev Yochay of Sheba Medical Center has deemed her research as “very worrisome."&nbsp;

However, she further said that it also gives a little optimism regarding the power of boosters to fight Omicron.

“The fact that Omicron is somewhat resistant to the vaccine is very much apparent when you’re only with two doses, and much less substantive after a third dose, she said during a media briefing.&nbsp;

Pfizer is expected to deliver an Omicron-based vaccine in March 2022. It is currently under development by BioNTech.

(With inputs from agencies)

As Omicron cases are rapidly spreading all across the world, a latest study has revealed that a three-shot course of the Pfizer-BioNTech Covid vaccine offers protection against the new variant, Omicron.

As Omicron cases are rapidly spreading all across the world, a latest study has revealed that a three-shot course of the Pfizer-BioNTech Covid vaccine offers protection against the new variant, Omicron. The study was carried out by the Sheba Medical Center and the Health Ministry’s Central Virology Laboratory. As a part of the study, a comparison was made between the blood of 20 people who had received two vaccine doses 5-6 months prior to the same number of people who had received a booster just a month before. The findings are very similar to those of a study presented by Pfizer-BioNTech a week before. The study stated that the vaccine neutralises the Omicron variant of coronavirus. Also read | Study demonstrates three doses of Pfizer-BioNTech vaccine neutralises Omicron variant Omicron counts more than 30 mutations on the spike protein. The company has said that although two doses of the vaccine offer a high level of protection, the third jab increases efficacy by 25 per cent. According to a report by Times of Israel, Prof. Gili Regev Yochay of Sheba Medical Center has deemed her research as “very worrisome." However, she further said that it also gives a little optimism regarding the power of boosters to fight Omicron. “The fact that Omicron is somewhat resistant to the vaccine is very much apparent when you’re only with two doses, and much less substantive after a third dose, she said during a media briefing. Pfizer is expected to deliver an Omicron-based vaccine in March 2022. It is currently under development by BioNTech. (With inputs from agencies)

Israeli study finds Pfizer booster to be effective against Omicron variant

According to an investigation by the UK-based Channel 4, drug major Pfizer allegedly paid experts to lie about Covid vaccine made by its rival AstraZeneca along with Oxford University. Pfizer has denied the claims being made in the investigative report to be aired on Friday.

As per the allegations, a panel of experts was paid to state things against AstraZeneca.

Both vaccines, one developed by Pfizer and another by AstraZeneca/ Oxford University were&nbsp;among the first ones to get Emergency Use Authorisation (EUA) by the World Health Organization.

As per accusations against Pfizer, the company paid experts to say that AstraZeneca's jab would cause cancer and won't be suitable for use in the case of immunosuppressed patients. The assertions were reportedly made in an educational seminar in Canada.

Pfizer has also been targeted for allegedly selling its vaccine at an inflated price. The vaccine cost just 1 dollar per dose to manufacture but the company charged UK government 29 dollars per dose.

Pfizer has reportedly 'vehemently denied' all the accusations. The pharma major has said that they were 'wrongly attributed' to it. Pfizer said that the presentations mentioned in the allegations were carried out by a third party.

According to an investigation by the UK-based Channel 4, drug major Pfizer allegedly paid experts to lie about Covid vaccine made by its rival AstraZeneca along with Oxford University.

According to an investigation by the UK-based Channel 4, drug major Pfizer allegedly paid experts to lie about Covid vaccine made by its rival AstraZeneca along with Oxford University. Pfizer has denied the claims being made in the investigative report to be aired on Friday. As per the allegations, a panel of experts was paid to state things against AstraZeneca. Both vaccines, one developed by Pfizer and another by AstraZeneca/ Oxford University were among the first ones to get Emergency Use Authorisation (EUA) by the World Health Organization. As per accusations against Pfizer, the company paid experts to say that AstraZeneca's jab would cause cancer and won't be suitable for use in the case of immunosuppressed patients. The assertions were reportedly made in an educational seminar in Canada. Pfizer has also been targeted for allegedly selling its vaccine at an inflated price. The vaccine cost just 1 dollar per dose to manufacture but the company charged UK government 29 dollars per dose. Pfizer has reportedly 'vehemently denied' all the accusations. The pharma major has said that they were 'wrongly attributed' to it. Pfizer said that the presentations mentioned in the allegations were carried out by a third party.

Investigative report claims Pfizer paid money to spread lies about AstraZeneca Covid jab

The head of US pharma giant, Pfizer, has said that yearly Covid vaccination might be necessary to maintain a “very high level of protection”.

Dr Albert Bourla, chief executive at the company which delivered the world's first Covid vaccine a year ago, said the countries may have to rely on jabs for many years to come to counter new variants and waning immunity.

Bourla told BBC that they are working on an updated vaccine for the Omicron variant, while adding that it could be ready in 100 days.

Also read |&nbsp;<a href="https://www.wionews.com/world/netherlands-belgium-germany-had-omicron-cases-a-week-before-safrica-identified-the-coronavirus-variant-433005">Netherlands, Belgium, Germany had Omicron cases a week before S.Africa identified the Coronavirus variant</a>

“If we have to make a guess based on everything I have seen so far, I would say that annual vaccinations...are likely to be needed to maintain a very robust and very high level of protection,” he said.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/india-news/omicron-in-india-dont-need-fear-says-health-ministry-as-first-2-cases-found-one-patient-fully-vaccinated-433526">Omicron in India: Don't need fear, says health ministry as first 2 cases found; one patient fully vaccinated</a>

He said that Pfizer had already updated vaccines in response to the Beta, first identified in South Africa, and Delta, first identified in India, variants but that they had not been needed.

Bourla was described as unapologetic about making profits from the jabs, saying they had saved “millions of lives” around the globe.

Also read |&nbsp;<a href="https://www.wionews.com/world/two-fully-vaccinated-israeli-doctors-get-infected-with-omicron-variant-433249">Two fully vaccinated Israeli doctors get infected with Omicron variant</a>

“We have saved the global economy trillions of dollars. It is a strong incentive for innovation for the next pandemic. But people will see that if they step up to the game, to bring something that saves lives and saves money, there is also a financial reward,” he said.

The call for yearly vaccination from the Pfizer head comes as the world braces itself to tackle a new Covid variant that first emerged from South Africa.

The Omicron coronavirus variant was designated as a “variant of concern” by the World Health Organization after they found that the new strain had the ability to bypass the immunity generated by the vaccines.

(With inputs from agencies)

The head of US pharma giant, Pfizer, has said that yearly Covid vaccination might be necessary to maintain a “very high level of protection”. Dr Albert Bourla, chief executive at the company which delivered the world's first Covid vaccine a year ago, said the countries may have to rely on jabs for many years to come to counter new variants and waning immunity.

The head of US pharma giant, Pfizer, has said that yearly Covid vaccination might be necessary to maintain a “very high level of protection”. Dr Albert Bourla, chief executive at the company which delivered the world's first Covid vaccine a year ago, said the countries may have to rely on jabs for many years to come to counter new variants and waning immunity. Bourla told BBC that they are working on an updated vaccine for the Omicron variant, while adding that it could be ready in 100 days. Also read | Netherlands, Belgium, Germany had Omicron cases a week before S.Africa identified the Coronavirus variant “If we have to make a guess based on everything I have seen so far, I would say that annual vaccinations...are likely to be needed to maintain a very robust and very high level of protection,” he said. Also read | Omicron in India: Don't need fear, says health ministry as first 2 cases found; one patient fully vaccinated He said that Pfizer had already updated vaccines in response to the Beta, first identified in South Africa, and Delta, first identified in India, variants but that they had not been needed. Bourla was described as unapologetic about making profits from the jabs, saying they had saved “millions of lives” around the globe. Also read | Two fully vaccinated Israeli doctors get infected with Omicron variant “We have saved the global economy trillions of dollars. It is a strong incentive for innovation for the next pandemic. But people will see that if they step up to the game, to bring something that saves lives and saves money, there is also a financial reward,” he said. The call for yearly vaccination from the Pfizer head comes as the world braces itself to tackle a new Covid variant that first emerged from South Africa. The Omicron coronavirus variant was designated as a “variant of concern” by the World Health Organization after they found that the new strain had the ability to bypass the immunity generated by the vaccines. (With inputs from agencies)

Yearly Covid vaccinations necessary to counter new variants, waning immunity: Pfizer boss

As concerns grow about the impact of the new Omicron variant, Pfizer announced on Tuesday it was seeking US authorization for booster shots for adolescents aged 16 and 17.

So far, FDA has approved emergency use authorizations (EUAs) for boosters only for those aged 18 and over, six months after the primary series of the Pfizer or Moderna Covid vaccine, or two months after the Johnson &amp; Johnson booster.

Also read |&nbsp;<a href="https://www.wionews.com/science/will-the-vaccines-stop-omicron-scientists-are-racing-to-find-out-432692">Will the vaccines stop Omicron? Scientists are racing to find out.</a>

"Today, we submitted a request to the @US_FDA to expand the emergency use authorization of a booster dose of our COVID-19 vaccine to include 16- and 17-year-olds," Pfizer CEO Albert Bourla wrote on Twitter.

"It is our hope to provide strong protection for as many people as possible, particularly in light of the new variant."&nbsp;

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
Today, we submitted a request to the <a href="https://twitter.com/US_FDA?ref_src=twsrc%5Etfw">@US_FDA</a> to expand the emergency use authorization of a booster dose of our COVID-19 vaccine to include 16- and 17-year-olds. It is our hope to provide strong protection for as many people as possible, particularly in light of the new variant.
— Albert Bourla (@AlbertBourla) <a href="https://twitter.com/AlbertBourla/status/1465804576372703241?ref_src=twsrc%5Etfw">November 30, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

Due to the mutation pattern detected on the Omicron variant, experts fear that protection offered by the current vaccine generation may be compromised.

Within a few weeks, lab results will reveal whether or not the hypothesis is correct. However, US health authorities are insisting that everyone who is eligible for a booster get one, to ensure protection against severe Covid, even if not infection itself.

While Omicron has been detected in more than a dozen countries, it has yet to be detected in the United States, where Delta accounts for more than 99 per cent of all infections.

Watch |&nbsp;Gravitas: India helps Africa amid Omicron alert

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-india-helps-africa-amid-omicron-alert-433080/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

There is disagreement among health experts regarding boosters for healthy teens, who are at less risk of developing severe Covid, especially when males exposed to the Pfizer and Moderna messenger RNA vaccines, are at higher risk of developing vaccine-linked myocarditis.

"If the FDA takes this action, it will be a total gamble," tweeted Vinay Prasad, a haematologist-oncologist at the University of San Francisco with expertise in biostatistics and epidemiology.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
As long as it is so uncertain, the decision must be made solely on the basis of what is best for those actually getting the shot. 
 
If the FDA takes this action it will be a total gamble 
 
it won't be the first one. 
 
But each of these gambles is dangerous.
— Vinay Prasad, MD MPH 🎙️📷 (@VPrasadMDMPH) <a href="https://twitter.com/VPrasadMDMPH/status/1465712589447446540?ref_src=twsrc%5Etfw">November 30, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

(With inputs from agencies)

As concerns grow about the impact of the new Omicron variant, Pfizer announced on Tuesday it was seeking US authorization for booster shots for adolescents aged 16 and 17.

As concerns grow about the impact of the new Omicron variant, Pfizer announced on Tuesday it was seeking US authorization for booster shots for adolescents aged 16 and 17. So far, FDA has approved emergency use authorizations (EUAs) for boosters only for those aged 18 and over, six months after the primary series of the Pfizer or Moderna Covid vaccine, or two months after the Johnson & Johnson booster. Also read | Will the vaccines stop Omicron? Scientists are racing to find out. "Today, we submitted a request to the @US_FDA to expand the emergency use authorization of a booster dose of our COVID-19 vaccine to include 16- and 17-year-olds," Pfizer CEO Albert Bourla wrote on Twitter. "It is our hope to provide strong protection for as many people as possible, particularly in light of the new variant." Today, we submitted a request to the @US_FDA to expand the emergency use authorization of a booster dose of our COVID-19 vaccine to include 16- and 17-year-olds. It is our hope to provide strong protection for as many people as possible, particularly in light of the new variant. — Albert Bourla (@AlbertBourla) November 30, 2021 × Due to the mutation pattern detected on the Omicron variant, experts fear that protection offered by the current vaccine generation may be compromised. Within a few weeks, lab results will reveal whether or not the hypothesis is correct. However, US health authorities are insisting that everyone who is eligible for a booster get one, to ensure protection against severe Covid, even if not infection itself. While Omicron has been detected in more than a dozen countries, it has yet to be detected in the United States, where Delta accounts for more than 99 per cent of all infections. Watch | Gravitas: India helps Africa amid Omicron alert There is disagreement among health experts regarding boosters for healthy teens, who are at less risk of developing severe Covid, especially when males exposed to the Pfizer and Moderna messenger RNA vaccines, are at higher risk of developing vaccine-linked myocarditis. "If the FDA takes this action, it will be a total gamble," tweeted Vinay Prasad, a haematologist-oncologist at the University of San Francisco with expertise in biostatistics and epidemiology. As long as it is so uncertain, the decision must be made solely on the basis of what is best for those actually getting the shot. If the FDA takes this action it will be a total gamble it won't be the first one. But each of these gambles is dangerous. — Vinay Prasad, MD MPH 🎙️📷 (@VPrasadMDMPH) November 30, 2021 × (With inputs from agencies)

Pfizer seeks US FDA approval for Covid boosters for teens aged 16-17

Pfizer's covid-19 vaccine seems to be promising for youngsters. New trial data shows that the jab is providing long-term efficacy in adolescents, here's the report.

Covid Vaccine News: Pfizer vaccine looms promising for youngsters

In what&nbsp;has been termed as a "a major milestone" by Health Canada, the country&nbsp;has now authorised the use of the Pfizer-BioNTech vaccine for children between 5 and 11. The decision comes in after a few companies sent an application requesting a clinical trial for thousands of children in this age group.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
(1/9) The NACI recommends two 10 mcg doses of the Pfizer-BioNTech Comirnaty <a href="https://twitter.com/hashtag/CovidVaccine?src=hash&amp;ref_src=twsrc%5Etfw">#CovidVaccine</a> may be offered to children 5-11 years of age, with at least 8 weeks between the first and second dose. Read the summary of NACI’s recommendations: <a href="https://t.co/W9RHyOe4RJ">https://t.co/W9RHyOe4RJ</a> <a href="https://t.co/y50P5qtLb7">pic.twitter.com/y50P5qtLb7</a>
— Health Canada and PHAC (@GovCanHealth) <a href="https://twitter.com/GovCanHealth/status/1461709661346926598?ref_src=twsrc%5Etfw">November 19, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

It was then concluded that the vaccine shows the same efficacy rate as those recorded in trials among adults aged 16 to 25.&nbsp;

"After a thorough and independent scientific review of the evidence, the department has determined that the benefits of this vaccine for children between five and 11 years of age outweigh the risks," said an official statement from Health Canada. 
It was found that the vaccine is 90 per cent effective at preventing the deadly coronavirus. Also, there were no serious side effects seen.

"To date, Health Canada has not identified any new safety issues for 5-11 year olds compared to the known safety profile in adolescents and young adults. Safety data will be continually monitored," Health Canada wrote on Twitter.&nbsp;

Earlier this year, Canada had authorised the same vaccine for children aged 12 years and up.

<a href="https://www.wionews.com/world/pfizer-strikes-usd-53-billion-deal-to-sell-10-million-covid-treatments-in-us-430309">Also read |&nbsp;Pfizer strikes USD 5.3 billion deal to sell 10 million COVID treatments in US</a>

As per data by Health Canada, nearly 75 per cent of all Canadians are fully vaccinated, including 84 per cent of those 12 and older.

Not just Canada but countries like Israel and the US have also authorised Pfizer-BioNTech's vaccine for children.&nbsp; 
China, the United Arab Emirates, Cambodia and Colombia have also started vaccinating children under 12. However, they are using Chinese vaccines.

Meanwhile, the pharma giant has struck a deal to sell 10 million Covid-19 treatment courses to the US government for USD 5.3 billion. It said that approval of the agreement was pending from regulators.&nbsp;

Pfizer will start delivering the treatments to the US government later this year and continue through the end of 2022.

(With inputs from agencies)

In what has been termed as a "a major milestone" by Health Canada, the country has now authorised the use of the Pfizer-BioNTech vaccine for children between 5 and 11.

In what has been termed as a "a major milestone" by Health Canada, the country has now authorised the use of the Pfizer-BioNTech vaccine for children between 5 and 11. The decision comes in after a few companies sent an application requesting a clinical trial for thousands of children in this age group. (1/9) The NACI recommends two 10 mcg doses of the Pfizer-BioNTech Comirnaty #CovidVaccine may be offered to children 5-11 years of age, with at least 8 weeks between the first and second dose. Read the summary of NACI’s recommendations: https://t.co/W9RHyOe4RJ pic.twitter.com/y50P5qtLb7 — Health Canada and PHAC (@GovCanHealth) November 19, 2021 × It was then concluded that the vaccine shows the same efficacy rate as those recorded in trials among adults aged 16 to 25. "After a thorough and independent scientific review of the evidence, the department has determined that the benefits of this vaccine for children between five and 11 years of age outweigh the risks," said an official statement from Health Canada. It was found that the vaccine is 90 per cent effective at preventing the deadly coronavirus. Also, there were no serious side effects seen. "To date, Health Canada has not identified any new safety issues for 5-11 year olds compared to the known safety profile in adolescents and young adults. Safety data will be continually monitored," Health Canada wrote on Twitter. Earlier this year, Canada had authorised the same vaccine for children aged 12 years and up. Also read | Pfizer strikes USD 5.3 billion deal to sell 10 million COVID treatments in US As per data by Health Canada, nearly 75 per cent of all Canadians are fully vaccinated, including 84 per cent of those 12 and older. Not just Canada but countries like Israel and the US have also authorised Pfizer-BioNTech's vaccine for children. China, the United Arab Emirates, Cambodia and Colombia have also started vaccinating children under 12. However, they are using Chinese vaccines. Meanwhile, the pharma giant has struck a deal to sell 10 million Covid-19 treatment courses to the US government for USD 5.3 billion. It said that approval of the agreement was pending from regulators. Pfizer will start delivering the treatments to the US government later this year and continue through the end of 2022. (With inputs from agencies)

'A major milestone': Canada approves Pfizer Covid-19 vaccine for kids aged 5-11

The United States authorised the&nbsp;Pfizer&nbsp;and Moderna Covid vaccine boosters to all people aged 18 and older on Friday,&nbsp;as the world's hardest-hit country enters a new winter wave of the pandemic.

Boosters were previously available to the immune compromised, over 65s, people at high risk of severe disease and people in high risk occupations.

The new decision "helps to provide continued protection against Covid-19, including the serious consequences that can occur, such as hospitalization and death," said acting FDA commissioner Janet Woodcock in a statement.

"This emergency use authorization comes at a critical time as we enter the winter months and face increasing Covid-19 case counts and hospitalizations across the country," added Moderna CEO Stephane Bancel.

ALSO READ | <a href="https://www.wionews.com/world/austria-to-impose-lockdown-as-europe-grapples-with-virus-surge-430542">Austria to impose lockdown as Europe grapples with virus surge</a>

The FDA said it based its decision on strong immune response data from hundreds of people dosed with the two vaccines.&nbsp;

Pfizer&nbsp;also carried out a clinical trial involving 10,000 people aged over 16 which found that the booster showed an efficacy against symptomatic infection of more than 95 percent compared to those who did not receive a booster.

This study was not cited by the FDA in making its decision, but it could nevertheless indicate the&nbsp;Pfizer&nbsp;vaccine works best as a three-dose shot -- or that the three-week time interval between first and second dose was never long enough to induce the best immune response.

Both vaccines are available to people six months after completing their primary series.&nbsp;

ALSO READ |&nbsp;<a href="https://www.wionews.com/world/us-army-to-bar-promotion-re-enlistment-for-soldiers-who-refuse-to-take-covid-vaccine-430505">US Army to bar promotion, re-enlistment for soldiers who refuse to take Covid vaccine</a>

Pfizer's vaccine is dosed at 30 micrograms, the same as the primary series, while Moderna's is 50 micrograms, half the primary series.

People who received the Johnson &amp; Johnson one dose vaccine were already eligible for a booster two months after their first shot.

The booster decision comes as cases are rapidly rising nationally, reaching 88,000 new infections per day on average as the country enters its fifth wave, according to the latest data.&nbsp;

Misgivings&nbsp;

The Centers for Disease Control and Prevention will hold a meeting later Friday to discuss clinical recommendations for who should now seek a vaccine.

The meeting should provide greater insight into the thinking of top federal advisors, some of whom have expressed misgivings about a "booster bonanza."

The vast majority of those people becoming hospitalized or dying with Covid are unvaccinated, and thus the best way to control the winter wave would be to reach those people, rather than topping up the vaccinated, the critics say.

A potential downside, they argue, is that vaccine holdouts might conclude the shots are ineffective.&nbsp;&nbsp;

Another risk is a greater number of cases of vaccine-linked heart inflammation (myocarditis), especially among younger males.&nbsp;

Both companies are conducting post authorization studies to assess the risks of myocarditis.

Experts are in broad agreement that boosters alone can't resolve the pandemic while the poorest countries, especially in Africa, remain stuck in the single digit percentages for people covered by their primary vaccination series.&nbsp;

Last week, WHO chief Tedros Adhanom Ghebreyesus decried the fact that rich countries are administering six times more vaccine doses everyday than low-income countries are delivering primary doses.

This increases the risk of new variants of concern emerging in those regions, which could eventually evade the protective action of current vaccines.

The United States authorised the Pfizer and Moderna Covid vaccine boosters to all people aged 18 and older on Friday, as the world's hardest-hit country enters a new winter wave of the pandemic.

The United States authorised the Pfizer and Moderna Covid vaccine boosters to all people aged 18 and older on Friday, as the world's hardest-hit country enters a new winter wave of the pandemic. Boosters were previously available to the immune compromised, over 65s, people at high risk of severe disease and people in high risk occupations. The new decision "helps to provide continued protection against Covid-19, including the serious consequences that can occur, such as hospitalization and death," said acting FDA commissioner Janet Woodcock in a statement. "This emergency use authorization comes at a critical time as we enter the winter months and face increasing Covid-19 case counts and hospitalizations across the country," added Moderna CEO Stephane Bancel. ALSO READ | Austria to impose lockdown as Europe grapples with virus surge The FDA said it based its decision on strong immune response data from hundreds of people dosed with the two vaccines. Pfizer also carried out a clinical trial involving 10,000 people aged over 16 which found that the booster showed an efficacy against symptomatic infection of more than 95 percent compared to those who did not receive a booster. This study was not cited by the FDA in making its decision, but it could nevertheless indicate the Pfizer vaccine works best as a three-dose shot -- or that the three-week time interval between first and second dose was never long enough to induce the best immune response. Both vaccines are available to people six months after completing their primary series. ALSO READ | US Army to bar promotion, re-enlistment for soldiers who refuse to take Covid vaccine Pfizer's vaccine is dosed at 30 micrograms, the same as the primary series, while Moderna's is 50 micrograms, half the primary series. People who received the Johnson & Johnson one dose vaccine were already eligible for a booster two months after their first shot. The booster decision comes as cases are rapidly rising nationally, reaching 88,000 new infections per day on average as the country enters its fifth wave, according to the latest data. Misgivings The Centers for Disease Control and Prevention will hold a meeting later Friday to discuss clinical recommendations for who should now seek a vaccine. The meeting should provide greater insight into the thinking of top federal advisors, some of whom have expressed misgivings about a "booster bonanza." The vast majority of those people becoming hospitalized or dying with Covid are unvaccinated, and thus the best way to control the winter wave would be to reach those people, rather than topping up the vaccinated, the critics say. A potential downside, they argue, is that vaccine holdouts might conclude the shots are ineffective. Another risk is a greater number of cases of vaccine-linked heart inflammation (myocarditis), especially among younger males. Both companies are conducting post authorization studies to assess the risks of myocarditis. Experts are in broad agreement that boosters alone can't resolve the pandemic while the poorest countries, especially in Africa, remain stuck in the single digit percentages for people covered by their primary vaccination series. Last week, WHO chief Tedros Adhanom Ghebreyesus decried the fact that rich countries are administering six times more vaccine doses everyday than low-income countries are delivering primary doses. This increases the risk of new variants of concern emerging in those regions, which could eventually evade the protective action of current vaccines.

COVID-19: US authorises boosters of the Pfizer/BioNTech and Moderna vaccines for all adults

Pharma giant Pfizer said on Thursday that it had struck a deal to sell 10 million Covid-19 treatment courses to US government for USD 5.3 billion. It said that approval of the agreement was pending from regulators. Pfizer will start delivering the treatments to the US government later this year and continuing through the end of 2022, a statement from the company said.&nbsp;

On Tuesday, Pfizer had asked US Food and Drug Administration (FDA) for emergency use authorisation of Paxlovid, the drug company's antiviral pill that has been observed to cut hospitalisation or death by nearly 90 percent among newly-infected high risk patients treated within three days of the onset of symptoms.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/us-pharma-giant-pfizers-covid-19-pill-to-be-manufactured-in-95-countries-429924/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

"It is encouraging to see a growing understanding of the valuable role that oral investigational therapies may play in combatting COVID-19, and we look forward to continuing discussions with governments around the world to help ensure broad access for people everywhere."

The move from Pfizer comes a few weeks after Merck approached FDA. Merck sought grren light for its antiviral capsule against coronavirus.

Also Read | <a href="https://www.wionews.com/world/pfizer-to-allow-other-companies-to-manufacture-covid-pill-in-95-countries-429793">Pfizer to allow other companies to manufacture Covid pill in 95 countries</a>

The US government announced in June it was investing $3 billion from the American Rescue Plan to accelerate the discovery, development and manufacturing of antiviral medicines.

"This promising treatment could help accelerate our path out of this pandemic by offering another life-saving tool for people who get sick with COVID-19," US health secretary Xavier Becerra said.&nbsp;

While vaccinations remain the most important step to end the pandemic, "This agreement would help ensure millions of doses of this drug would be available to the American people if it is authorized," he said.

The US is also buying 3.1 million courses of the Merck pill, Molnupiravir.

Pfizer has also entered into advance purchase agreements with several other countries and has initiated bilateral outreach to approximately 100 countries around the world, and is committed to working on "equitable access" for the treatment at an affordable price.

It announced a deal Tuesday with the UN-backed Medicines Patent Pool (MPP) to sub-license production for supply in 95 low- and middle-income nations covering around 53 percent of the world's population.

Paxlovid is a combination of a new molecule, PF-07321332, and HIV antiviral ritonavir. Both belong to a class of antivirals called "protease inhibitors," which block the action of an enzyme critical to viral replication.

A treatment course consists of one pill every 12 hours for five days.

(With inputs from agencies)

Pharma giant Pfizer said on Thursday that it had struck a deal to sell 10 million Covid-19 treatment courses to US government for USD 5.3 billion. It said that approval of the agreement was pending from regulators.

Pharma giant Pfizer said on Thursday that it had struck a deal to sell 10 million Covid-19 treatment courses to US government for USD 5.3 billion. It said that approval of the agreement was pending from regulators. Pfizer will start delivering the treatments to the US government later this year and continuing through the end of 2022, a statement from the company said. On Tuesday, Pfizer had asked US Food and Drug Administration (FDA) for emergency use authorisation of Paxlovid, the drug company's antiviral pill that has been observed to cut hospitalisation or death by nearly 90 percent among newly-infected high risk patients treated within three days of the onset of symptoms. × "It is encouraging to see a growing understanding of the valuable role that oral investigational therapies may play in combatting COVID-19, and we look forward to continuing discussions with governments around the world to help ensure broad access for people everywhere." The move from Pfizer comes a few weeks after Merck approached FDA. Merck sought grren light for its antiviral capsule against coronavirus. Also Read | Pfizer to allow other companies to manufacture Covid pill in 95 countries The US government announced in June it was investing $3 billion from the American Rescue Plan to accelerate the discovery, development and manufacturing of antiviral medicines. "This promising treatment could help accelerate our path out of this pandemic by offering another life-saving tool for people who get sick with COVID-19," US health secretary Xavier Becerra said. While vaccinations remain the most important step to end the pandemic, "This agreement would help ensure millions of doses of this drug would be available to the American people if it is authorized," he said. The US is also buying 3.1 million courses of the Merck pill, Molnupiravir. Pfizer has also entered into advance purchase agreements with several other countries and has initiated bilateral outreach to approximately 100 countries around the world, and is committed to working on "equitable access" for the treatment at an affordable price. It announced a deal Tuesday with the UN-backed Medicines Patent Pool (MPP) to sub-license production for supply in 95 low- and middle-income nations covering around 53 percent of the world's population. Paxlovid is a combination of a new molecule, PF-07321332, and HIV antiviral ritonavir. Both belong to a class of antivirals called "protease inhibitors," which block the action of an enzyme critical to viral replication. A treatment course consists of one pill every 12 hours for five days. (With inputs from agencies)

Pfizer strikes USD 5.3 billion deal to sell 10 million COVID treatments in US

Did Pfizer, BioNTech & Moderna prioritise their Wuhan virus vaccine supplies to rich countries to make billions in profits? A report has claimed that the companies are making $1000 per second in profits from their shots. Palki Sharma tells you more.

Gravitas: 3 companies. 2 Covid-19 vaccines. $34 Billion in profits

U.S. pharma giant Pfizer has signed a license-sharing deal one that will allow its experimental COVID-19 pill to be manufactured in 95 countries. This means that the pill will be easily available to more than half of the globe.

U.S. pharma giant Pfizer's COVID-19 pill to be manufactured in 95 countries

South Korea is facing a rapid surge in coronavirus cases despite achieving a high rate of inoculation. The country is mulling to reduce the gap for booster doses from six to four months.

According to Korea Disease Control and Prevention Agency (KDCA), ''Despite our high vaccination rate, we've confirmed clear rises in breakthrough infections among senior generations four months after they got the shot.''

''There is also a growing need for additional vaccination doses due to declining immunity from the Delta variants and as time passes.''&nbsp;

<a href="https://www.wionews.com/technology/south-korea-to-clamp-down-on-cryptocurrency-phishing-activity-383873">Also read |&nbsp;South Korea to clamp down on cryptocurrency phishing activity&nbsp;</a>

Driving serious and critical cases to a record, elderly people above the age of 60 constitute more than 82 per cent of the record jump from the mid-300s in October to 460 on Wednesday.

South Korea's overall rate of vaccine breakthrough infections remains low at 85.5 people per every 100,000 inoculated.

However, as vaccine protection wanes over time, older people's immune system, which is much weaker than young people is making them more vulnerable to infections.

<a href="https://www.wionews.com/world/semen-terrorism-angers-women-in-south-korea-404805">Also read |&nbsp;'Semen terrorism' angers women in South Korea</a>

As per the data released by the government, out of the total serious and critical patients with vaccine breakthrough infections in the past eight weeks, 93 per cent were from those aged 60 and above.

''The increase is not posing a threat to the country's healthcare system yet, as there are nearly 500 ICU beds available, said senior health ministry official Son Young-rae.

The country has inoculated 640,232 people with a booster shot, since the programme began last month, mainly using vaccines from Pfizer/BioNTech and Moderna.

South Korea started a gradual easing of COVID-19 restrictions this month, as it has fully vaccinated nearly 90 per cent&nbsp;of its adult population, or 77 per cent&nbsp;of its 52 million people.

The authorities have said a circuit breaker will be issued when there is a major strain on the number of hospital beds to treat serious cases, but have not revealed the exact threshold.

The country reported 2,425 new cases for Tuesday. It has recorded a total of 385,831 infections, with 3,012 deaths so far.

(With inputs from agencies)

South Korea is facing a rapid surge in coronavirus cases despite achieving a high rate of inoculation. The country is mulling to reduce the gap for booster doses from six to four months.

South Korea is facing a rapid surge in coronavirus cases despite achieving a high rate of inoculation. The country is mulling to reduce the gap for booster doses from six to four months. According to Korea Disease Control and Prevention Agency (KDCA), ''Despite our high vaccination rate, we've confirmed clear rises in breakthrough infections among senior generations four months after they got the shot.'' ''There is also a growing need for additional vaccination doses due to declining immunity from the Delta variants and as time passes.'' Also read | South Korea to clamp down on cryptocurrency phishing activity Driving serious and critical cases to a record, elderly people above the age of 60 constitute more than 82 per cent of the record jump from the mid-300s in October to 460 on Wednesday. South Korea's overall rate of vaccine breakthrough infections remains low at 85.5 people per every 100,000 inoculated. However, as vaccine protection wanes over time, older people's immune system, which is much weaker than young people is making them more vulnerable to infections. Also read | 'Semen terrorism' angers women in South Korea As per the data released by the government, out of the total serious and critical patients with vaccine breakthrough infections in the past eight weeks, 93 per cent were from those aged 60 and above. ''The increase is not posing a threat to the country's healthcare system yet, as there are nearly 500 ICU beds available, said senior health ministry official Son Young-rae. The country has inoculated 640,232 people with a booster shot, since the programme began last month, mainly using vaccines from Pfizer/BioNTech and Moderna. South Korea started a gradual easing of COVID-19 restrictions this month, as it has fully vaccinated nearly 90 per cent of its adult population, or 77 per cent of its 52 million people. The authorities have said a circuit breaker will be issued when there is a major strain on the number of hospital beds to treat serious cases, but have not revealed the exact threshold. The country reported 2,425 new cases for Tuesday. It has recorded a total of 385,831 infections, with 3,012 deaths so far. (With inputs from agencies)

South Korea battling rapid surge in COVID-19 cases despite nearly 90% vaccination rate

Pharma giant Pfizer and UN-backed international public health group Medicines Patent Pool (MPP) on Tuesday struck a licensing agreement over Pfizer's&nbsp;COVID-19 pill. The agreement will allow MPP to grant sub-licenses to qualified generic drug manufacturers across the world to make their own versions of the Covid pill. Pfizer will sell the pills it manufactures under the brand name Paxlovid.

Pfizer already makes one of the most widely used COVID-19 vaccines. The company said that the Covid pill has cut the chance of hospitalisation or death for adults at risk of severe disease by 89% in its clinical trial. The drug will be used in combination with ritonavir, an HIV drug that is already available generically.

Pfizer's licensing deal follows a similar arrangement by rival Merck &amp; Co for generic manufacturing of its COVID-19 treatment. The deals are unusual arrangements that acknowledge the dire need for effective treatments as well as the pressure drugmakers are under to make their life-saving drugs accessible at very low costs.

Also Read | <a href="https://www.wionews.com/world/pfizers-experimental-covid-pill-reduces-hospitalisations-and-deaths-company-claims-426982">Pfizer's experimental Covid pill reduces hospitalisations and deaths, company claims</a>

"We are extremely pleased to have another weapon in our armoury to protect people from the ravages of COVID-19," Charles Gore, Executive Director of the Medicines Patent Pool, said in an interview.

Gore said he hoped the generic version of Pfizer's drug will be available within months.

The 95 countries in the license agreement cover around 53% of the world's population and include all low- and lower-middle-income countries and some upper-middle-income countries in Sub-Saharan Africa. They also include countries that have transitioned from lower-middle to upper-middle-income status in the past five years, Pfizer and the MPP said.

Pfizer will waive royalties on sales in low-income countries. It will also waive them in the other countries covered by the agreement as long as COVID-19 remains classified as a public health emergency of international concern by the World Health Organization.

Pfizer's version of the drug will be in high demand. The company has said it expects to manufacture 180,000 treatment courses by the end of next month and at least 50 million courses by the end of 2022.

(With inputs from agencies)

Pharma giant Pfizer and UN-backed international public health group Medicines Patent Pool (MPP) on Tuesday struck a licensing agreement over Pfizer's COVID-19 pill.

Pharma giant Pfizer and UN-backed international public health group Medicines Patent Pool (MPP) on Tuesday struck a licensing agreement over Pfizer's COVID-19 pill. The agreement will allow MPP to grant sub-licenses to qualified generic drug manufacturers across the world to make their own versions of the Covid pill. Pfizer will sell the pills it manufactures under the brand name Paxlovid. Pfizer already makes one of the most widely used COVID-19 vaccines. The company said that the Covid pill has cut the chance of hospitalisation or death for adults at risk of severe disease by 89% in its clinical trial. The drug will be used in combination with ritonavir, an HIV drug that is already available generically. Pfizer's licensing deal follows a similar arrangement by rival Merck & Co for generic manufacturing of its COVID-19 treatment. The deals are unusual arrangements that acknowledge the dire need for effective treatments as well as the pressure drugmakers are under to make their life-saving drugs accessible at very low costs. Also Read | Pfizer's experimental Covid pill reduces hospitalisations and deaths, company claims "We are extremely pleased to have another weapon in our armoury to protect people from the ravages of COVID-19," Charles Gore, Executive Director of the Medicines Patent Pool, said in an interview. Gore said he hoped the generic version of Pfizer's drug will be available within months. The 95 countries in the license agreement cover around 53% of the world's population and include all low- and lower-middle-income countries and some upper-middle-income countries in Sub-Saharan Africa. They also include countries that have transitioned from lower-middle to upper-middle-income status in the past five years, Pfizer and the MPP said. Pfizer will waive royalties on sales in low-income countries. It will also waive them in the other countries covered by the agreement as long as COVID-19 remains classified as a public health emergency of international concern by the World Health Organization. Pfizer's version of the drug will be in high demand. The company has said it expects to manufacture 180,000 treatment courses by the end of next month and at least 50 million courses by the end of 2022. (With inputs from agencies)

Pfizer to allow other companies to manufacture Covid pill in 95 countries

Taiwan’s health minister Chen Shih-chung has said that they are suspending&nbsp;second doses of the Pfizer-BioNTech (BNT) Covid vaccine to children in the 12-17 age group amid concerns that it may increase the risk of myocarditis.

He said that a panel of experts will review the data on cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart) and will decide on the further course of action in two weeks, according to local Taiwanese media.

“Taiwan's Advisory Committee on Immunization Practices had decided to hold off on administering second doses to the 12-17 age group and will meet in two weeks to make a final decision on the matter,” he was quoted as saying.

During these two weeks, experts on the committee will collect and review data on cases of myocarditis and pericarditis in other countries and Taiwan, Chen said.

According to Central Epidemic Command Center spokesperson Chuang Jen-hsiang, 1.1 million people aged between 12-17 have received their first dose of the Pfizer-BioNTech vaccine in Taiwan.

Out of those, 17 cases of myocarditis or pericarditis have been reported. Fourteen of the patients were male and three were female, Chuang said.

Some countries have adjusted their policies regarding administering COVID-19 vaccines to adolescents. For instance, Hong Kong has changed from two doses of BNT to only a single dose for those aged 12-17. The U.K. has done something similar, recommending only one shot for children between 12 and 18 years of age, according to news outlet CNA.

(With inputs from agencies)

Taiwan’s health minister Chen Shih-chung has said that they are suspending second doses of the Pfizer-BioNTech (BNT) Covid vaccine to children in the 12-17 age group amid concerns that it may increase the risk of myocarditis.

Taiwan’s health minister Chen Shih-chung has said that they are suspending second doses of the Pfizer-BioNTech (BNT) Covid vaccine to children in the 12-17 age group amid concerns that it may increase the risk of myocarditis. He said that a panel of experts will review the data on cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart) and will decide on the further course of action in two weeks, according to local Taiwanese media. “Taiwan's Advisory Committee on Immunization Practices had decided to hold off on administering second doses to the 12-17 age group and will meet in two weeks to make a final decision on the matter,” he was quoted as saying. During these two weeks, experts on the committee will collect and review data on cases of myocarditis and pericarditis in other countries and Taiwan, Chen said. According to Central Epidemic Command Center spokesperson Chuang Jen-hsiang, 1.1 million people aged between 12-17 have received their first dose of the Pfizer-BioNTech vaccine in Taiwan. Out of those, 17 cases of myocarditis or pericarditis have been reported. Fourteen of the patients were male and three were female, Chuang said. Some countries have adjusted their policies regarding administering COVID-19 vaccines to adolescents. For instance, Hong Kong has changed from two doses of BNT to only a single dose for those aged 12-17. The U.K. has done something similar, recommending only one shot for children between 12 and 18 years of age, according to news outlet CNA. (With inputs from agencies)

Taiwan suspends 2nd dose Pfizer Covid vaccine for 12-17 olds over heart inflammation

WHO approved Covaxin earlier, but Pfizer's vaccine trial questioned over data integrity, regulatory oversight

Was Pfizer's vaccine trial compromised?

Was Pfizer's Wuhan Virus vaccine trial compromised? A whistleblower who worked for the company hired to run the trial spotted several lapses. She was allegedly fired after she sent a complaint to US FDA. Palki Sharma brings you a report.

Gravitas: Was Pfizer's Covid-19 vaccine trial "compromised"?

Pfizer has claimed that their experimental pill against the deadly coronavirus has the capacity to reduce the risk of hospitalisation and deaths in high-risk patients.<o:p></o:p>

The pharmaceutical company has revealed that the interim analysis before the end of the trial has shown that there is an 89 per cent decline in risk of hospitalisations and Covid deaths. However, the data has not been peer reviewed yet.<o:p></o:p>

Pfizer has been testing this pill in high-risk adult Covid patients. In these trials, some of the volunteers have been given the pill combination while others have been given a placebo, within three to five days of the start of their symptoms.<o:p></o:p>

As per the collected data, only 0.8 per cent of volunteers (three out of 389) who were given the pill combination within three days of symptoms were hospitalised. The data showed a stark contrast with the volunteers who were given a placebo. Nearly seven per cent of volunteers had to be hospitalised and eventually passed away from the disease. However, none of the volunteers who were given the pill succumbed to the virus.

<o:p><a href="https://www.wionews.com/videos/worlds-first-pill-to-treat-covid-gets-approval-in-uk-heres-all-you-need-to-know-426907">WATCH |</a></o:p>

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/worlds-first-pill-to-treat-covid-gets-approval-in-uk-heres-all-you-need-to-know-426907/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

"Similar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset; 1% of patients who received PF-07321332 (with) ritonavir were hospitalized through Day 28 following randomization (6/607 hospitalized, with no deaths), compared to 6.7% of patients who received a placebo," the company said.<o:p></o:p>

It has also been revealed that 19 per cent of volunteers who were given the pill suffered some reactions, which were missing in the patients who got a placebo. However, it was not made clear what these reactions were or what was the intensity.<o:p></o:p>

"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients' lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations," Albert Bourla, chairman CEO of Pfizer, said in a statement.<o:p></o:p>

With the experimental name PF-07321332, this pill is designed to stop the virus from multiplying and is supposed to slow the breakdown in the body when given with ritonavir.<o:p></o:p>

Pfizer has claimed that their experimental pill against the deadly coronavirus has the capacity to reduce the risk of hospitalisation and deaths in high-risk patients.

Pfizer has claimed that their experimental pill against the deadly coronavirus has the capacity to reduce the risk of hospitalisation and deaths in high-risk patients. The pharmaceutical company has revealed that the interim analysis before the end of the trial has shown that there is an 89 per cent decline in risk of hospitalisations and Covid deaths. However, the data has not been peer reviewed yet. Pfizer has been testing this pill in high-risk adult Covid patients. In these trials, some of the volunteers have been given the pill combination while others have been given a placebo, within three to five days of the start of their symptoms. As per the collected data, only 0.8 per cent of volunteers (three out of 389) who were given the pill combination within three days of symptoms were hospitalised. The data showed a stark contrast with the volunteers who were given a placebo. Nearly seven per cent of volunteers had to be hospitalised and eventually passed away from the disease. However, none of the volunteers who were given the pill succumbed to the virus. WATCH | "Similar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset; 1% of patients who received PF-07321332 (with) ritonavir were hospitalized through Day 28 following randomization (6/607 hospitalized, with no deaths), compared to 6.7% of patients who received a placebo," the company said. It has also been revealed that 19 per cent of volunteers who were given the pill suffered some reactions, which were missing in the patients who got a placebo. However, it was not made clear what these reactions were or what was the intensity. "These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients' lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations," Albert Bourla, chairman CEO of Pfizer, said in a statement. With the experimental name PF-07321332, this pill is designed to stop the virus from multiplying and is supposed to slow the breakdown in the body when given with ritonavir.

Pfizer's experimental Covid pill reduces hospitalisations and deaths, company claims

Pfizer's kid-size COVID-19 injection received final approval from US health regulators on Tuesday, paving the way for a substantial extension of the country's vaccination campaign to include children as young as 5.

The Food and Drug Administration has previously approved the injections for children aged 5 to 11.&nbsp;

The dosages given to teenagers and adults are just a third of what is given to teens and adults.

The Centers for Disease Control and Prevention, on the other hand, makes explicit recommendations on who should receive FDA-approved vaccines. 
 
Also Read:&nbsp;<a href="https://www.wionews.com/world/as-vaccine-mandate-deadline-looms-new-york-city-braces-for-workers-shortage-425259" hreflang="en">As vaccine mandate deadline looms, New York City braces for workers’ shortage</a>

Dr Rochelle Walensky, director of the CDC, made the news just hours after an advisory council unanimously recommended that Pfizer's vaccines should be made available to the 28 million children in that age bracket.&nbsp;

During a day of live-streamed deliberations, the CDC assembled a panel of independent experts to analyse the existing data on the state of the outbreak in children, the efficiency of Pfizer's vaccine, and its likely adverse effects.&nbsp;

Since the FDA approval, "there hasn't been a moment that teams have not been picking, packing and shipping vaccines," Jeff Zients, the White House pandemic coordinator, said Monday. 
 
Watch | Rise in COVID-19 cases among children in Israel trigger noticeable jump

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/rise-in-covid-19-cases-among-children-in-israel-trigger-noticeable-jump-419987/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

"We are planning on some vaccinations towards the end of this week," he said, adding that the programme will be "really hitting full strength the week of November 8."

Last week, FDA officials debated whether every young kid required vaccination.

COVID-19-infected children are more likely to develop high-risk diseases, including obesity or diabetes.

However, otherwise healthy youngsters can get critically ill, and the CDC's advisors eventually advised the injections for all of them, including those who had already recovered from a COVID-19 infection.&nbsp;

(With inputs from agencies)

Pfizer's kid-size COVID-19 injection received final approval from US health regulators on Tuesday, paving the way for a substantial extension of the country's vaccination campaign to include children as young as 5.

Pfizer's kid-size COVID-19 injection received final approval from US health regulators on Tuesday, paving the way for a substantial extension of the country's vaccination campaign to include children as young as 5. The Food and Drug Administration has previously approved the injections for children aged 5 to 11. The dosages given to teenagers and adults are just a third of what is given to teens and adults. The Centers for Disease Control and Prevention, on the other hand, makes explicit recommendations on who should receive FDA-approved vaccines. Also Read: As vaccine mandate deadline looms, New York City braces for workers’ shortage Dr Rochelle Walensky, director of the CDC, made the news just hours after an advisory council unanimously recommended that Pfizer's vaccines should be made available to the 28 million children in that age bracket. During a day of live-streamed deliberations, the CDC assembled a panel of independent experts to analyse the existing data on the state of the outbreak in children, the efficiency of Pfizer's vaccine, and its likely adverse effects. Since the FDA approval, "there hasn't been a moment that teams have not been picking, packing and shipping vaccines," Jeff Zients, the White House pandemic coordinator, said Monday. Watch | Rise in COVID-19 cases among children in Israel trigger noticeable jump "We are planning on some vaccinations towards the end of this week," he said, adding that the programme will be "really hitting full strength the week of November 8." Last week, FDA officials debated whether every young kid required vaccination. COVID-19-infected children are more likely to develop high-risk diseases, including obesity or diabetes. However, otherwise healthy youngsters can get critically ill, and the CDC's advisors eventually advised the injections for all of them, including those who had already recovered from a COVID-19 infection. (With inputs from agencies)

COVID-19 vaccine for children: US gives final nod to Pfizer jabs for 5-11 age group

The United States has approved Pfizer-BioNTech’s COVID-19 vaccine for children from the ages of 5 to 11, it is a major milestone in country's fight against the pandemic.

United States: CDC approves Pfizer-BioNTech’s COVID-19 vaccine for children

The US Centers for Disease Control and Prevention (CDC) has officially approved Pfizer-BioNTech’s COVID-19 vaccine for children from the ages of 5 to 11. This means that up to 28 million children in the age group will be eligible for the shots.

US CDC approves Pfizer's COVID-19 vaccine for children ages 5 to 11

The United States on Monday provided as many as 100,620 doses of Pfizer COVID-19 vaccines to Nepal through COVAX. This adds up to the 1.53 million J&amp;J vaccines given by the US to Nepal in July.

Nepal has been using various COVID-19 vaccines manufactured by different companies that they have received under the COVAX programme besides the ones they purchased from India and China.&nbsp;

The US Embassy announced on Twitter, “100,620 doses of Pfizer vaccine have just arrived in Nepal. These vaccines have been donated by the US government to Nepal to fight COVID-19 in partnership with COVAX. Stay tuned for more.”

US Ambassador to Nepal, Randy Berry, who also happens to mark her third anniversary as the Ambassador to Nepal, further committed to supporting Nepal to fight the pandemic.&nbsp;

<img alt="US donates 100,620 doses of Pfizer vaccines to Nepal" data-entity-type="file" data-entity-uuid="6731b8f5-0ef4-467e-bd53-07853e572d19" src="//cdn.wionews.com/sites/default/files/inline-images/FChDxztWYAAYZcz.jpeg" />

“I am beyond thrilled that today we donated 100,620 Pfizer COVID-19 vaccines to Nepal. This is part of our ongoing commitment to the Nepali people since the beginning of the pandemic, including 1.53 million J&amp;J vaccines. Beyond vaccines, our assistance to-date totals over $122M,” Ambassador Berry said in a tweet.&nbsp;

<a href="https://www.wionews.com/south-asia/china-has-been-breaching-nepal-china-border-rules-in-humla-report-423358">Also read |&nbsp;China has been breaching Nepal-China border rules in Humla: Report</a>

“Along with today's donation, USAID and #COVAX partners helped to ensure safe cold storage and handling of these vaccines to get shots in arms. This will benefit Nepalis now and in the future,” he said in another tweet.&nbsp;

The Nepal Foreign Ministry thanked the US for its help and support in combating the coronavirus pandemic through shipments of COVID-19 vaccine doses.&nbsp;

“The US has provided 100,620 doses of Pfizer vaccines in support of Nepal's vaccination drive. The vaccines received through COVAX is in addition to the earlier tranche of 1.53 million doses. Nepal is grateful for the generosity extended by the US at this critical time,” MoFA said in a tweet.&nbsp;

The donation comes two days after the Ambassador met the Nepali Health Minister in Kathmandu.&nbsp;

“Today, as part of regular diplomatic engagement, Ambassador Berry met with Health Minister Birodh Khatiwada. The two discussed bilateral issues including cooperation on COVID-19,” the Embassy had earlier said in a tweet. &nbsp;

As of Sunday, 8,606,988 Nepalis have received at least one dose of the anti-COVID vaccine, which is 28.3 per cent of the total population.&nbsp;

Likewise, 6,604,173 people have received both doses, which is nearly 22 per cent of the country’s population.&nbsp;

Nepal’s recovery currently stands at 97.3 per cent. The active cases stand at 1.53 per cent and the death rate is at 1.4 per cent.&nbsp;

The United States on Monday provided as many as 100,620 doses of Pfizer COVID-19 vaccines to Nepal through COVAX. This adds up to the 1.53 million J&J vaccines given by the US to Nepal in July.

The United States on Monday provided as many as 100,620 doses of Pfizer COVID-19 vaccines to Nepal through COVAX. This adds up to the 1.53 million J&J vaccines given by the US to Nepal in July. Nepal has been using various COVID-19 vaccines manufactured by different companies that they have received under the COVAX programme besides the ones they purchased from India and China. The US Embassy announced on Twitter, “100,620 doses of Pfizer vaccine have just arrived in Nepal. These vaccines have been donated by the US government to Nepal to fight COVID-19 in partnership with COVAX. Stay tuned for more.” US Ambassador to Nepal, Randy Berry, who also happens to mark her third anniversary as the Ambassador to Nepal, further committed to supporting Nepal to fight the pandemic. “I am beyond thrilled that today we donated 100,620 Pfizer COVID-19 vaccines to Nepal. This is part of our ongoing commitment to the Nepali people since the beginning of the pandemic, including 1.53 million J&J vaccines. Beyond vaccines, our assistance to-date totals over $122M,” Ambassador Berry said in a tweet. Also read | China has been breaching Nepal-China border rules in Humla: Report “Along with today's donation, USAID and #COVAX partners helped to ensure safe cold storage and handling of these vaccines to get shots in arms. This will benefit Nepalis now and in the future,” he said in another tweet. The Nepal Foreign Ministry thanked the US for its help and support in combating the coronavirus pandemic through shipments of COVID-19 vaccine doses. “The US has provided 100,620 doses of Pfizer vaccines in support of Nepal's vaccination drive. The vaccines received through COVAX is in addition to the earlier tranche of 1.53 million doses. Nepal is grateful for the generosity extended by the US at this critical time,” MoFA said in a tweet. The donation comes two days after the Ambassador met the Nepali Health Minister in Kathmandu. “Today, as part of regular diplomatic engagement, Ambassador Berry met with Health Minister Birodh Khatiwada. The two discussed bilateral issues including cooperation on COVID-19,” the Embassy had earlier said in a tweet. As of Sunday, 8,606,988 Nepalis have received at least one dose of the anti-COVID vaccine, which is 28.3 per cent of the total population. Likewise, 6,604,173 people have received both doses, which is nearly 22 per cent of the country’s population. Nepal’s recovery currently stands at 97.3 per cent. The active cases stand at 1.53 per cent and the death rate is at 1.4 per cent.

US donates 100,620 doses of Pfizer vaccines to Nepal

pfizer

Pfizer, News on Pfizer, stories on Pfizer, articles on Pfizer, Pfizer stories at Wion, Pfizer news, Pfizer latest news